Peritoneal Metastasis Clinical Trial
Official title:
Machine Learning Models for Predicting Postoperative Peritoneal Metastasis After Hepatocellular Carcinoma Rupture
NCT number | NCT06102278 |
Other study ID # | PM-01 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 1, 2020 |
Est. completion date | April 1, 2023 |
Verified date | October 2023 |
Source | Tongji Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study aimed to address the issue of peritoneal metastasis (PM) following the rupture of hepatocellular carcinoma (HCC) and its adverse impact on patient prognosis. Clinical data from 522 patients with ruptured HCC who underwent surgery at seven different medical centers were collected and analyzed. Machine learning models were employed for analysis and prediction.
Status | Completed |
Enrollment | 522 |
Est. completion date | April 1, 2023 |
Est. primary completion date | March 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria:(1) HCC confirmed by pathologists (2) two preoperative imaging findings suggestive of tumor rupture (3) R0 resection (4) first tumor detection - Exclusion Criteria:(1) previous antitumor therapy (2) combination of other types of tumors (3) incomplete clinical data - |
Country | Name | City | State |
---|---|---|---|
China | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Chen Xiaoping |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | overall survival | Overall survival (OS) was defined as the time from the date of surgery to death | 2018-2023 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05544253 -
Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC
|
Phase 2/Phase 3 | |
Recruiting |
NCT02591667 -
Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer
|
Phase 2 | |
Completed |
NCT01242436 -
Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Ovarian Cancer and Peritoneal Metastasis
|
N/A | |
Recruiting |
NCT02779608 -
The Study of Intraperitoneal Docetaxel Plus S-1 for Malignant Ascites
|
Phase 2 |